301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC
Scarfo, Irene, Lim, Laura, Dang, Kevin, Chew, Marvin, Sudhakah, Rakesh, Nguyen, Michelle, Mohanty, Suchismita, Chen, Jeremy, Gomez, Alma, Attanasio, Nickolas, Fearon, Amanda, Chan, Ivan, Sail, Vibhavari, Gardner, Thomas J, Millare, Beatriz, Zhang, James, Moskowitz, Darrian, Thomas, Vince, Zhou, Stanley, Smith, Jenessa, McDevitt, Jennifer, Boroughs, Angela
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
Development of AB-2100, an autologous integrated circuit T (ICT) cell therapy targeting CA9 intended for the treatment of ccRCC
Landon, Mark, Scarfo, Irene, Chew, Marvin, Sudhakah, Rakesh, Nguyen, Michelle, Mohanty, Suchismita, Chen, Jeremy, Gomez, Alma, Attanasio, Nickolas, Fearon, Amanda, Chan, Ivan, Sail, Vibhavari, Gardner, Thomas, Millare, Beatriz, Thomas, Vince, Zhou, Stanley, Smith, Jenessa, Mcdevitt, Jennifer, Boroughs, Angela, Gray-Rupp, Levi
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Abstract 38: AB-2100, a PSMA-inducible CA9-specific CAR T cell product for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model
Mohanty, Suchismita, Chen, Jeremy, Gomez, Alma, Boroughs, Angela, Scarfo, Irene, Lim, Laura, Dang, Kevin, Chew, Marvin, Sudhakah, Rakesh, Nguyen, Michelle, Gardner, Thomas J., Millare, Beatriz, Zhang, James, Moskowitz, Darrian, Zhou, Stanley, Xie, Neroli H., Attanasio, Nickolas, Fearon, Amanda, Chan, Ivan, Sail, Vibhavari, Thomas, Vince, Smith, Jennesa, McDevitt, Jennifer, Gray-Rupp, Levi, Gonzalez, Alba, Murriel, Christopher, Haining, W. Nicholas
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article